RGLS4326 RG4326|cas:2229964-07-0|西域试剂

RGLS4326 RG4326,98%

产品编号：Bellancom-139290| CAS NO：2229964-07-0| 分子式：C₉₅H₁₁₅F₃N₃₂O₅₁P₈S₈| 分子量：3082.42

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-139290		￥8700.00	杭州北京（现货）
Bellancom-139290		￥19000.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

RGLS4326 RG4326

产品介绍

RGLS4326 (RG4326) 是一种首创的 microRNA-17 (miR-17) 寡核苷酸抑制剂。RGLS4326 可用于常染色体显性多囊肾病 (ADPKD) 的研究。RGLS4326 作用于 HeLa 细胞，抑制 miR-17 功能，EC₅₀ 值为 28.3 nM。

生物活性

RGLS4326 (RG4326) is a first-in-class, short oligonucleotide inhibitor of microRNA-17 (miR-17). RGLS4326 can be used for the research of autosomal dominant polycystic kidney disease (ADPKD). RGLS4326 inhibits miR-17 function in HeLa cells with an EC₅₀ value of 28.3 nM.

体外研究

RGLS4326, a single-stranded, chemically modified, short oligonucleotide of 9-nt with full complementarity to the miR-17 seed sequence. RGLS4326 inhibits the pathologic functions of the miR-17 family of miRNAs in ADPKD.
RGLS4326 treatment inhibits miR-17 function in kidney collecting duct cells in culture as measured by miR-17 PD-Sig, with an EC₅₀ value of 77.2 ± 20.2 nM.
RGLS4326 suppresses the growth of primary human autosomal dominant polycystic kidney disease (ADPKD) cysts.

XIYU has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay

Cell Line:	Primary cysts in 3D Matrigel
Concentration:	5, 20, 100, and 300 nM
Incubation Time:	9 days
Result:	Decreased in cyst epithelial cell proliferation.

体内研究
(In Vivo)

RGLS4326 preferentially distributes to kidney tubules and cysts. RGLS4326 (a single 30 mg/kg SC injection) is rapidly absorbed into plasma, showing T_max of ≤1 h, C_max of 8.5 µg/mL, and half-life of <4 h in wild-type mice.
In vivo administration of RGLS4326 also upregulates the expression of the direct miR-17 target genes Pkd1 and Pkd2.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Pkd2-KO mice
Dosage:	20 mg/kg
Administration:	SC injection
Result:	Compared to non-cystic control kidneys, polycystic kidneys of PBS-treated Pkd2-KO mice exhibit an age-dependent progressive decline in miR-17 PD-Sig, indicative of increasing miR-17 activity with disease progression. Administration of RGLS4326 reversed this decline in miR-17 PD-Sig, indicating a sustained functional inhibition of miR-17.

体内研究

XIY has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Pkd2-KO mice
Dosage:	20 mg/kg
Administration:	SC injection
Result:	Compared to non-cystic control kidneys, polycystic kidneys of PBS-treated Pkd2-KO mice exhibit an age-dependent progressive decline in miR-17 PD-Sig, indicative of increasing miR-17 activity with disease progression. Administration of RGLS4326 reversed this decline in miR-17 PD-Sig, indicating a sustained functional inhibition of miR-17.

体内研究

XIYU has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Pkd2-KO mice
Dosage:	20 mg/kg
Administration:	SC injection
Result:	Compared to non-cystic control kidneys, polycystic kidneys of PBS-treated Pkd2-KO mice exhibit an age-dependent progressive decline in miR-17 PD-Sig, indicative of increasing miR-17 activity with disease progression. Administration of RGLS4326 reversed this decline in miR-17 PD-Sig, indicating a sustained functional inhibition of miR-17.

性状

Solid

溶解性数据

In Vitro:

H₂O : ≥ 100 mg/mL (32.44 mM)

* "≥" means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	0.3244 mL	1.6221 mL	3.2442 mL
5 mM	0.0649 mL	0.3244 mL	0.6488 mL
10 mM	0.0324 mL	0.1622 mL	0.3244 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (stored under nitrogen)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

-20°C, stored under nitrogen

*In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

参考文献

. Edmund C Lee, et al. Discovery and preclinical evaluation of anti-miR-17 oligonucleotide RGLS4326 for the treatment of polycystic kidney disease. Nat Commun. 2019 Sep 12;10(1):4148. [Content Brief]

化学品安全说明书(MSDS)

下载MSDS

RGLS4326 RG4326,98%

RGLS4326 RG4326

化学品安全说明书(MSDS)

质检证书(COA)

在线咨询